ProstaLund Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Anders Kristensson

İcra Kurulu Başkanı

SEK 2.3m

Toplam tazminat

CEO maaş yüzdesi	17.2%
CEO görev süresi	1.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.3yrs

Son yönetim güncellemeleri

Recent updates

We Think ProstaLund (STO:PLUN) Can Afford To Drive Business Growth

May 12

CEO Tazminat Analizi

Anders Kristensson'un ücretlendirmesi ProstaLund'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-SEK 22m
Mar 31 2024	n/a	n/a	-SEK 19m
Dec 31 2023	SEK 2m	SEK 394k	-SEK 17m

Tazminat ve Piyasa: Anders 'ın toplam tazminatı ($USD 213.69K ) Swedish pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 243.31K ).

Tazminat ve Kazançlar: Anders şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Anders Kristensson (50 yo)

1.1yrs

Görev süresi

SEK 2,291,833

Tazminat

Mr. Anders Kristensson has been the Chief Executive Officer of ProstaLund AB (publ) since October 2023. Mr. Kristensson served as the CEO of TikoMed AB. He has several years of experience from the Pharma i...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anders Kristensson	Chief Executive Officer	1.1yrs	SEK 2.29m	Veri yok
Niclas Nystroom	Chief Financial Officer	less than a year	Veri yok	Veri yok
Erika Carlsson	Chief Operating Officer	2.8yrs	Veri yok	0% SEK 0
Johan Laven	Director of Sales & Marketing	less than a year	Veri yok	Veri yok
Charlotta Andersson	Sales Manager and Clinical Instructor - Sweden & Finland	no data	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim: PLUN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Paul de Potocki	Independent Director	1.1yrs	SEK 20.13k	Veri yok
Marianne Ostlund	Independent Director	4.8yrs	SEK 96.60k	0.076% SEK 26.8k
Sonny Schelin	Director	12.8yrs	SEK 76.48k	0.058% SEK 20.4k
Tomas Eriksson	Independent Director	1.1yrs	SEK 20.13k	Veri yok
Annette Colin	Independent Director	1.5yrs	SEK 64.40k	Veri yok
Lars Johansson	Independent Director	2.5yrs	SEK 142.89k	0% SEK 0
Per Langoo	Independent Chairman	1.1yrs	SEK 50.31k	Veri yok
Tom Roonnlund	Independent Director	1.1yrs	SEK 20.13k	Veri yok

1.3yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PLUN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

ProstaLund Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

ProstaLund AB (publ), Annual General Meeting, May 30, 2024

Director recently bought kr98k worth of stock

Director recently bought kr81k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

High number of new directors

Second quarter 2024 earnings released: kr0.094 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Shareholder dilution

First quarter 2024 earnings released: kr0.062 loss per share (vs kr0.056 loss in 1Q 2023)

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.21 loss in FY 2022)

ProstaLund AB (publ), Annual General Meeting, May 30, 2024

New major risk - Financial position

Third quarter 2023 earnings released: kr0.082 loss per share (vs kr0.04 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.072 loss in 2Q 2022)

Director recently bought kr98k worth of stock

ProstaLund AB (publ) Decides to Withdraw its 510(k) Application and Intend Instead to Submit a De Novo Application for Schelin Catheter® in the US

Prostalund AB (Publ) Announces Successfully Used At Asst Grande Ospedale Metropolitano Niguarda

First quarter 2023 earnings released: kr0.056 loss per share (vs kr0.042 loss in 1Q 2022)

Full year 2022 earnings released: kr0.21 loss per share (vs kr0.17 loss in FY 2021)

Director recently bought kr81k worth of stock

ProstaLund AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

ProstaLund Receives CE Approval Under MDR for its New Treatment Platform Coretherm® Eagle

High number of new and inexperienced directors

ProstaLund Files its 510(k) Application to the FDA for the Schelin Catheter

High number of new and inexperienced directors

Prostalund AB (Publ) Announces Coreflow® - Soft Stent - First Patient in the Uk Under Treatment

Insider recently bought kr229k worth of stock

Less than half of directors are independent

We Think ProstaLund (STO:PLUN) Can Afford To Drive Business Growth

Full year 2021 earnings released

ProstaLund Successfully Introduces Schelin Catheter as Tool

ProstaLund AB (publ) to Report Q1, 2022 Results on May 11, 2022

ProstaLund AB (publ), Annual General Meeting, May 05, 2022

ProstaLund AB (publ) Receives Utility Patent in China

Second quarter 2021 earnings released: kr0.066 loss per share (vs kr0.096 loss in 2Q 2020)

Chief Financial Officer exercised options to buy kr461k worth of stock.

Chief Financial Officer exercised options to buy kr453k worth of stock.

Prostalund Signs A Four-Year Framework Agreement with the Västra Götaland Region

New 90-day high: kr5.90

Third quarter earnings released

New 90-day high: kr3.11

New 90-day high - kr2.58

First half earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş